Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab [1]

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1457-1458

  Ruiz Jimeno, Teresa ^a   Carvajal, Alejandra ^a   Mata, Cristina ^a   Aurrecoechea, Elena ^a  

^a HOSPITAL SIERRALLANA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; GADOLINIUM; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ATAXIA; BLOOD BRAIN BARRIER; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; DEMYELINATING DISEASE; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; GAIT DISORDER; HEART FAILURE; HUMAN; INFECTION RISK; LETTER; LYMPHOMA; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RELATIVE; RISK BENEFIT ANALYSIS; TUBERCULOSIS; VISUAL IMPAIRMENT; WEAKNESS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DEMYELINATING DISEASES; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; RISK FACTORS; SPINAL CORD;

EID: 33745800627     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Hyrich KL, Silman AJ, Watson KD, Symmons DPM. Anti-tumor necrosis factor α therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 2004;63:1538-43.
2. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
3. Cisternas M, Gutiérrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan, et al. Arthritis Rheum 2002;46:3107-8.
4. van der Laken CJ, Lems WF, van Soesbergen RM, van der Sande JJ, Dijkmans BAC. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan, et al. Arthritis Rheum 2003;48:269-70.
5. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65.
6. Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism. By what mechanisms could tumor necrosis factor á antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001;44:1977-83.
7. Poser CM. Multiple sclerosis trait: the premorbid stage of multiple sclerosis. A hypothesis. Acta Neurol Scand 2004;109:239-43.
8. Wilier CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Nat Acad Sci USA 2003;100:12877-82.
9. Becanovic K, Jagodic M, Wallstrom E, Olsson T. Current gene-mapping strategies in experimental models of multiple sclerosis. Scand J Immunol 2004;60:39-51.
10. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Ann Rheum Dis 2005;44:157-63.